Selpercatinib | List of Frontiers open access articles

Case Report

Published on 15 Jan 2025

Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case

in Cancer Molecular Targets and Therapeutics

Raffaella Pagliaro
Paola Maria Medusa
Fabiana Vitiello
Luigi Aronne
Susan F. M. Campbell
Fabio Perrotta
Andrea Bianco

Frontiers in Oncology

doi 10.3389/fonc.2024.1500449

2,989 views
3 citations

Case Report

Published on 18 May 2023

Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer

in Thoracic Oncology

Jonathan W. Goldman
Lynette M. Sholl
Sanja Dacic
Michael C. Fishbein
Yonina R. Murciano-Goroff
Ravi Rajaram
Sylwia Szymczak
Anna M. Szpurka
Bo H. Chao
Alexander Drilon

Frontiers in Oncology

doi 10.3389/fonc.2023.1178313

5,676 views
5 citations

Case Report

Published on 19 Nov 2024

Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review

in Cancer Molecular Targets and Therapeutics

Kaidiriye Setiwalidi
Yimeng Li
Yuyan Ma
Zhanpeng Hao
Yujia Zhao
Yuxin Zhang
Xuan Liang
Tao Tian
Zhiping Ruan

Frontiers in Oncology

doi 10.3389/fonc.2024.1431908

2,771 views
2 citations

Case Report

Published on 10 Jul 2023

Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion–positive non–small cell lung cancer: a case report

in Thoracic Oncology

Daniela Scattolin
Elena Scagliori
Antonio Scapinello
Alberto Fantin
Valentina Guarneri
Giulia Pasello

Frontiers in Oncology

doi 10.3389/fonc.2023.1201599

3,439 views
5 citations

Case Report

Published on 07 Feb 2024

Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC

in Thoracic Oncology

Elisa De Carlo
Elisa Bertoli
Monica Schiappacassi
Brigida Stanzione
Alessandro Del Conte
Roberto Doliana
Michele Spina
Alessandra Bearz

Frontiers in Oncology

doi 10.3389/fonc.2024.1307458

3,008 views
3 citations

Case Report

Published on 09 Oct 2023

Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report

in Thoracic Oncology

Caio Abner Leite
Raíssa Pierri Carvalho
Felipe Marques da Costa
Augusto Kreling Medeiros
Fabio Augusto Schutz
William Nassib William

Frontiers in Oncology

doi 10.3389/fonc.2023.1264231

3,535 views
10 citations

Original Research

Published on 13 Jan 2025

Research on detection methods of related substances and degradation products of the antitumor drug selpercatinib

in Analytical Chemistry

Jingjing Xiang
Liangliang Cai
Qin Wang
Yonghong Zhu
Yong Han

Frontiers in Chemistry

doi 10.3389/fchem.2024.1534132

2,576 views
1 citation

Case Report

Published on 24 Dec 2024

Case report: Eczematous adverse drug reaction after selpercatinib treatment

in Pharmacology of Anti-Cancer Drugs

Bingrun Li
Peng Cao
Wenjing Xu
Litao Zhang

Frontiers in Oncology

doi 10.3389/fonc.2024.1475541

2,007 views
1 citation

Original Research

Published on 16 Oct 2025

BYS10, a novel selective RET inhibitor, exhibits potent antitumor activity in preclinical models

in Pharmacology of Anti-Cancer Drugs

Fei Qin
Yiman Chen
Jinhai Deng
Ruizhi Guo
Zhoufan Xie
Zhibo Luo
Lin Wang
Tianbai Huang
Jiaji Zhao
Jiansong Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1670140

1,759 views
1 citation

Original Research

Published on 20 Sep 2024

Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system

in Pharmacology of Anti-Cancer Drugs

Qiong Jie
Yuanyuan Li
Li Jing
Jinjin Chen
Yang Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1424980

4,998 views
7 citations

Case Report

Published on 14 Mar 2023

Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report

in Thoracic Oncology

Aakriti Arora
Jacob Zaemes
Metin Ozdemirli
Chul Kim

Frontiers in Oncology

doi 10.3389/fonc.2023.1134151

3,647 views
11 citations

Case Report

Published on 25 Apr 2023

Case Report: A case of ultra-late recurrence of KIF13A-RET fusion non-small cell lung cancer response to selpercatinib

in Thoracic Oncology

Ha-Young Park
Joo-Heon Park
Myung-Geun Shin
Seung Jung Han
Yong-Sok Ji
Hyung-Joo Oh
Young-Chul Kim
Taebum Lee
Yoo-Duk Choi
In-Jae Oh

Frontiers in Oncology

doi 10.3389/fonc.2023.1178762

3,204 views
6 citations

Mini Review

Published on 14 Feb 2023

A comprehensive overview of the relationship between RET gene and tumor occurrence

in Cancer Genetics

Lu Zhao
Na Wang
Dou Zhang
Yingjie Jia
Fanming Kong

Frontiers in Oncology

doi 10.3389/fonc.2023.1090757

11,759 views
17 citations

Brief Research Report

Published on 06 Nov 2025

Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer

in Head and Neck Cancer

Yulu Zhou
Junjie Cao
Siqi Zhang
Mingjun Sun
Yaqi Zhang
Songzhe Li
Zining Luo
Pengyu Wang
Jiebin Xie

Frontiers in Oncology

doi 10.3389/fonc.2025.1683624

2,404 views

Original Research

Published on 27 Jan 2025

RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer

in Breast Cancer

Charlotte K. Kindt
Sidse Ehmsen
Sofie Traynor
Benedetta Policastro
Nikoline Nissen
Mie K. Jakobsen
Monique F. Hundebøl
Lene E. Johansen
Martin Bak
Elsa Arbajian

Frontiers in Oncology

doi 10.3389/fonc.2024.1497093

4,834 views
1 citation

Mini Review

Published on 23 Aug 2021

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue

in Thoracic Oncology

Shinkichi Takamori
Taichi Matsubara
Naoki Haratake
Gouji Toyokawa
Takatoshi Fujishita
Ryo Toyozawa
Kensaku Ito
Masafumi Yamaguchi
Kenichi Taguchi
Tatsuro Okamoto

Frontiers in Oncology

doi 10.3389/fonc.2021.704084

11,090 views
15 citations

Articles

Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case

Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer

Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review

Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion–positive non–small cell lung cancer: a case report

Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC

Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report

Research on detection methods of related substances and degradation products of the antitumor drug selpercatinib

Case report: Eczematous adverse drug reaction after selpercatinib treatment

BYS10, a novel selective RET inhibitor, exhibits potent antitumor activity in preclinical models

Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system

Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report

Case Report: A case of ultra-late recurrence of KIF13A-RET fusion non-small cell lung cancer response to selpercatinib

A comprehensive overview of the relationship between RET gene and tumor occurrence

Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer

RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue